Abstract
The therapeutic efficacy of nebulised pentamidine in the prophylaxis of Pneumocystis carinii pneumonia (PCP) depends on the absolute pulmonary deposition of the drug. We studied the performance of a new nebuliser (Pentasave) by comparison both in vitro and in vivo with a standard nebuliser (Respirgard 11). In vitro, deposition of pentamidine labelled with technetium-99m human serum albumin was measured indirectly by capturing inhaled particles on an absolute filter and measuring radioactivity with a gamma camera. The nebulisers were initially assessed with a pentamidine dose of 100 mg in 5 ml at 44 psi and an air flow of 101/min for Respirgard II and 16 1/min for Pentasave. Nebuliser output, expressed as the percentage of the initial nebuliser radioactivity captured by the inhalation filter, was 15%±2% (mean±SD) for Respirgard 11, and significantly increased to 23%±3% for an initial version and to 33%±2% for the final version of Pentasave. Measurements with a gamma camera in a group of ten patients with human immunodeficiency virus infection were made in vivo. The results revealed that pulmonary drug distributions are good using both Respirgard II and Pentasave. The literature reports that once-monthly pulmonary deposition of 9 mg pentamidine seems enough to produce prophylactic effects against Pneumocystis carinii. We measured pulmonary pentamidine deposition of 20.22±4.31 mg (mean ±SD) using Respirgard 11 (with 300 mg in 5 m1) and of 16.00±7.18 mg using Pentasave (with 150 mg in 6 ml). These findings show that the therapeutic dose of pentamidine (9 mg) was widely exceeded with both nebulisers. Further investigations might demonstrate that about 200 mg and 125 mg pentamidine for Respirgard II and Pentasave, respectively, will achieve a pulmonary deposition of therapeutic dose, allowing significant savings in terms of drug and expense.
Similar content being viewed by others
References
Martin MA, Cox PH, Beck K, Styer CM, Beall GN. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Arch Intern Med 1992; 152:523–528.
Jorde UP, Horowitz HW, Wormser GP. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals. AIDS 1993;7:355–359.
Montgomery AB, Debs RJ, Luce JM, Corkery KJ, Turner J, Brunette EN, Lin ET, Hopewell PC. Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Lancet 1987;11:480–483.
Golden JA, Chernoff D, Hollander H, Feigal D, Conte JE. Prevention of Pneumocystis carinii pneumonia by inhaled pentamidine. Lancet 1989;1:654–657.
Girard P-M, Landman R, Gaudebout C, Lepretre A, Lottin P, Michon C, De Truchis P, Matheron S, Camus F, Farinotti R, Marche C, Coulaud JP, Saimot AG. Prevention of Pneumocystis carinii pneumonia relapse by pentamidine aerosol in zidovudine-treated AIDS patients. Lancet 1989;1:1348–1353.
Simonds AK, Newman SP, Johnson MA, Lee CA, Clarke SW. Alveolar targeting of aerosolised pentamidine. Am Rev Respir Dis 1989;139:A249.
Ong ELC, Dunbar EM, Mandal BK. Efficacy and effects on pulmonary function tests of weekly 600 mg aerosol pentamidine as prophylaxis against Pneumocystis carinii pneumonia. Infection 1992:20:136–139.
O'Doherty MJ, Thomas SHL, Gibb D, Page CJ, Harrington C, Duggan C, Nunan TO, Bateman NT. Lung deposition of nebulised pentamidine in children. Thorax 1993;48:220–226.
Lidman C, Tynell E, Berglund O, Lindback S. Aerosolized pentamidine versus i.v. pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Infection 1993;21: 146–149.
O'Doherty MJ, Thomas S, Page C, Barlow D, Bradbeer C, Nunan TO, Bateman NT. Differences in relative efficiency of nebulisers for pentamidine administration. Lancet 1988;11: 1283–1286.
Thomas SHL, Langford JA, George RDG, Geddes DM. Improving the efficiency of drug administration using jet nebulisers. Lancet 1988;1:126.
Simonds AK, Newman SP, Johnson MA, Lee CA, Talaee N, Clarke SW. Simple nebuliser modification to enhance alveolar deposition of pentamidine. Lancet 1989;11:953.
Smaldone GC, Fuhrer J, Stiegbigel RT, McPeck M. Factors determining pulmonary deposition of aerosolized pentamidine in patients with human immunodeficiency virus infection. Am Rev Respir Dis 1991;143:727–737.
O'Doherty MJ, Thomas S, Page C, Clark AR, Mitchell D, Heduan E, Nunan TO, Bateman NT. Does Tc99m human serum albumin alter the characteristics of nebulised pentamidine isethionate? Nucl Med Commun 1989;10: 523–529.
Thomas SHL, O'Doherty MJ, Page CJ, Nunan TO, Bateman NT. Which apparatus for inhaled pentamidine? A comparison of pulmonary deposition via eight nebulisers. Eur Respir J 1991;4:616–622.
Simonds AK, Newman SP, Johnson MA, Talaee N, Lee CA, Clarke SW. Aerosolised pentamidine. Lancet 1989;1:221–222.
Chen BT, Cheng YS, Yeh HC. Performance of a TSI aerodynamic particle sizer. Aerosol Sci Technol 1985;4:89–97.
O'Doherty MJ, Thomas S, Page C, Bradbeer C, Nunan TO, Bateman NT. Pulmonary deposition of nebulised pentamidine isethionate: effect of nebuliser type, dose, and volume of fill. Thorax 1990;45:460–464.
Thomas SHL, O'Doherty MJ, Page CJ, Nunan TO. Variability in the measurement of nebulized aerosol deposition in man. Clin Sci 1991;81:767–775.
Forge NI, Mountford PJ, O'Doherty MJ. Quantification of technetium-99m lung radioactivity from planar images. Eur J Nucl Med 1993;20:10–15.
Macey DJ, Marshall R. Absolute quantitation of radiotracer uptake in the lungs using a gamma camera. J Nucl Med 1982;23:731–735.
Rudolf G, Gebhart J, Heyder J, Scheunch G, Stahlhofen W. Mass deposition from inspired polydisperse aerosols. Ann Occup Hyg 1988;32:919–938.
Leoung GS, Feigal DW, Montgomery AB, Corkery K, Wardlaw L, Adams M, Bush D, Gordon S, Jacobson MA, Volberding PA, Abrams D, and The San Francisco County Community Consortium. Aerosolized pentamidine for prophylaxis against Pneumocystis carinii pneumonia. N Engl J Med 1990;323: 769–775.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ferretti, P.P., Versari, A., Gafà, S.I. et al. Pulmonary deposition of aerosolised pentamidine using a new nebuliser: efficiency measurements in vitro and in vivo. Eur J Nucl Med 21, 399–406 (1994). https://doi.org/10.1007/BF00171414
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00171414